Rare diseases
Investigational molecules
Locations
Wagistrasse 13, 8952
AL-S Pharma AG demonstrates a focused commitment to advancing treatments for complex neuropsychiatric conditions. The company's research portfolio centers on developing innovative pharmaceutical interventions for disorders affecting cognitive function and mental health. Their work addresses critical unmet medical needs in populations experiencing significant impairment in daily functioning and quality of life due to neurological and psychiatric manifestations.
The therapeutic development efforts emphasize conditions where current treatment options remain limited, focusing on novel mechanisms of action that may offer improved efficacy and tolerability profiles. This research direction reflects a strategic emphasis on neuropharmacological innovation targeting specific neurotransmitter systems and neural pathways implicated in complex brain disorders.
AL-S Pharma AG runs clinical trials in conditions such as Amyotrophic lateral sclerosis, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
SwedenIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
